Phase 3 N=109 tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12 PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
Diabetes · Gastroparesis With Diabetes Mellitus
Primary: Uptake of 11C-ER 176 in the Stomach Muscle — 5.5; 8.4; 4.6; 7.8 SUVmax
Phase 3 N=2,431 MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
Meningococcal Vaccine
Primary: Percentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month…
Phase 3 N=204 VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
SARS-CoV Infection
Primary: Efficacy of Sabizabulin in the Treatment of SARS-CoV-2 Infection by Assessing Its Effect on the Proportion of Patients Who Died on Study. — 25; 27 Participants
Phase 3 N=201 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
Overweight · Obesity
Primary: Change in Body Mass Index (BMI) (Percentage [%]) — -16.2; -0.1 Percentage change of BMI — p=<.0001
Phase 3 N=238 Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Biochemical Failure (Primary Endpoint of Revised Protocol) — 17.3; 12.8 percentage of participants — p=0.55
Phase 3 N=403 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Lymphoma
Primary: Primary Analysis: Progression Free Survival (PFS): Stratified Analysis — 23.75; 40.51 months — p=0.0922
Phase 3 N=601 Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
CMV Disease
Primary: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant — 10.4; 11.8 Percentage of Participants
Phase 3 N=343 Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Hematopoietic Stem Cells
Primary: Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days — NA; NA days — p=<0.001
Phase 3 N=36 The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Phase 3 N=455 ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
Oral Mucositis
Primary: Cumulative Incidence of Severe Oral Mucositis — 53.8; 64.0 percentage of patients
Phase 3 N=306 Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Pediatric Crohn's Disease
Primary: Percent of Participants Experiencing Treatment Failure — 25.64; 34.04 percentage of participants — p=0.08
Phase 3 N=1,407 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
Phase 3 N=993 Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
RSV
Primary: Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of…
Phase 3 N=230 Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate — 65; 66 participants